Keyphrases
Clinical Trials
100%
Cystic Fibrosis
100%
Clinical Efficacy
100%
F508del
100%
CF Transmembrane Conductance Regulator
100%
Lumacaftor-ivacaftor
100%
Forced Expiratory Volume in 1 Second (FEV1)
33%
Hospitalization Rate
33%
Sweat Chloride
33%
Confidence Interval
33%
Post-approval Changes
16%
Lung Function
16%
Therapeutic Development
16%
Developmental Networks
16%
Lumacaftor
16%
Ivacaftor
16%
Multicenter Cohort
16%
Prior Exposure
16%
Longitudinal Cohort Study
16%
Pulmonary Exacerbation
16%
Body Mass Index
16%
Infection Rate
16%
6-year-olds
16%
Clinically Significant Change
16%
Patient-initiated
16%
Follow-up Time
16%
P. Aeruginosa Infection
16%
Absolute Change
16%
Cystic Fibrosis Transmembrane Conductance Regulator
16%
Pseudomonas Aeruginosa Infection
16%
Medicine and Dentistry
Cystic Fibrosis
100%
Clinical Trial
100%
Patient with Cystic Fibrosis
100%
Ivacaftor
100%
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Lumacaftor
100%
Sweat
28%
Forced Expiratory Volume
28%
Lung
14%
Infection
14%
Cohort Analysis
14%
Pseudomonas aeruginosa
14%
Body Mass Index
14%
Pseudomonas Infection
14%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
100%
Cystic Fibrosis
100%
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Ivacaftor
100%
Lumacaftor
100%
Pseudomonas aeruginosa
28%
Forced Expiratory Volume
28%
Cohort Study
14%
Body Mass
14%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Lumacaftor
100%
Cystic Fibrosis
100%
Ivacaftor
100%
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Cohort Study
14%
Infection
14%
Pseudomonas aeruginosa
14%
Pseudomonas Infection
14%